-0.23 | -14.84%
| Price and Volume | |
|---|---|
| Recent Price | 1.32 |
| 52 Week High | 5.00 |
| 52 Week Low | 0.75 |
| Avg. Daily Vol. (Mil) | 0.00 |
| Beta (3 year) | 1.09 |
| Share Related Items | |
| Mkt Cap (Mil) | 16.07 |
| Shares Out (Mil) | 12.17 |
| Float (Mil) | 2.60 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 0.70 |
| Current Ratio | 1.20 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 10.90 |
| Price/Book | 0.00 |
| Price/Cash Flow | -2.10 |
| Per Share Data | |
| Earnings | -1.32 |
| Sales | 0.12 |
| Book Value | 0.00 |
| Cash Flow | -0.63 |
| Business Summary | |
|---|---|
| Oragenics, InCorporation is a multifaceted biopharmaceutical Company which focuses on the discovery, development and commercialization of a variety of technologies associated with oral health, broad spectrum antibiotics and other general health benefits. | |
| General Information | |
| 3000 Bayport Drive
Suite 685 Tampa, FL 33607 |
|
| www.oragenics.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 15 | |
| CEO: Dr. John N. Bonfiglio, P | |
| Short Interest | |
| Current Month (Mil) | 0.00 |
| Previous Month (Mil) | 0.01 |
| Short Interest Ratio (Days) | 0.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -398.50 |
| Return on Investments | -168.00 |
| Profitability | |
| Gross Margin | 50.00 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,437.23 | 1,315.94 | 2,834.30 | 16.47 |
Oil *
104.15
|
|
DOWN
143.46 |
DOWN
16.48 |
DOWN
36.69 |
DOWN
0.84 |
10 Yr
1.65%
SPDR Gold
149.51
|
|
-1.14%
|
-1.24%
|
-1.28%
|
-4.85%
|
Data delayed 20 minutes |
Connect with TheStreet